ReviewCancer management and research2025
Exploring the Therapeutic Potential of Ferroptosis in Gastric Cancer.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis as a Therapeutic Vulnerability to Overcome Chemoresistance in Gastric Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis refers to the regulatory cell death type with the typical feature of iron-dependent lipid peroxidation (LPO), which has been implicated in various aspects of cancer development and progression. Ferroptosis dysregulation can promote the occurrence, metastasis, and therapy resistance of gastric cancer (GC). Understanding the ferroptosis-related molecular mechanisms in GC progression could lead to novel therapeutic strategies that target this pathway. This review briefly introduces the mechanisms of ferroptosis and concludes that targeting ferroptosis can regulate the sensitivity of GC cells to chemotherapy resistance and immunotherapy. Natural plant extracts and traditional medicine play a key role in the treatment of GC by inducing ferroptosis through pathways such as activating p53 and inhibiting nuclear factor erythrocyte 2-related factor 2 (NRF2). Additionally, novel nanoparticle materials can be used as a drug carrier to promote ferroptosis while suppressing GC cell or gastric cancer stem cell (GCSC) growth, providing a novel direction for treating GC. It also summarizes other drugs such as 6-Thioguanine, Polymerase theta, levobupivacaine and clinical application drugs, which target ferroptosis, the effect of them in treating GC. This review highlights the potential of ferroptosis induction in GC treatment, providing new avenues for clinical intervention. Finally, this review looks forward to the translational prospects of targeting ferroptosis in the development of GC treatment, offering key insights for future research directions and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.